176 related articles for article (PubMed ID: 19882381)
21. In vitro synergy of pseudolaric acid B and fluconazole against clinical isolates of Candida albicans.
Guo N; Ling G; Liang X; Jin J; Fan J; Qiu J; Song Y; Huang N; Wu X; Wang X; Deng X; Deng X; Yu L
Mycoses; 2011 Sep; 54(5):e400-6. PubMed ID: 21910756
[TBL] [Abstract][Full Text] [Related]
22. Requirement for Ergosterol in Berberine Tolerance Underlies Synergism of Fluconazole and Berberine against Fluconazole-Resistant
Xu Y; Quan H; Wang Y; Zhong H; Sun J; Xu J; Jia N; Jiang Y
Front Cell Infect Microbiol; 2017; 7():491. PubMed ID: 29238700
[No Abstract] [Full Text] [Related]
23. In vitro activity of 2-cyclohexylidenhydrazo-4-phenyl-thiazole compared with those of amphotericin B and fluconazole against clinical isolates of Candida spp. and fluconazole-resistant Candida albicans.
De Logu A; Saddi M; Cardia MC; Borgna R; Sanna C; Saddi B; Maccioni E
J Antimicrob Chemother; 2005 May; 55(5):692-8. PubMed ID: 15772140
[TBL] [Abstract][Full Text] [Related]
24. Potential of plant oils as inhibitors of Candida albicans growth.
Devkatte AN; Zore GB; Karuppayil SM
FEMS Yeast Res; 2005 Jun; 5(9):867-73. PubMed ID: 15925315
[TBL] [Abstract][Full Text] [Related]
25. Drug resistance genes and trailing growth in Candida albicans isolates.
Lee MK; Williams LE; Warnock DW; Arthington-Skaggs BA
J Antimicrob Chemother; 2004 Feb; 53(2):217-24. PubMed ID: 14688046
[TBL] [Abstract][Full Text] [Related]
26. Reassessment of the in vitro synergistic effect of fluconazole with the non-steroidal anti-inflammatory agent ibuprofen against Candida albicans.
Arai R; Sugita T; Nishikawa A
Mycoses; 2005 Jan; 48(1):38-41. PubMed ID: 15679664
[TBL] [Abstract][Full Text] [Related]
27. [Derivatization of berberine based on its synergistic antifungal activity with fluconazole against fluconazole-resistant Candida albicans].
Tian SJ; Gao Y; Zang CX; Cai Z; Ni TJ; Tan SL; Cao YB; Jiang YY; Zhang DZ
Yao Xue Xue Bao; 2014 Nov; 49(11):1563-8. PubMed ID: 25757282
[TBL] [Abstract][Full Text] [Related]
28. Impact of endpoint definition on the outcome of antifungal susceptibility tests with Candida species: 24- versus 48-h incubation and 50 versus 80% reduction in growth.
St-Germain G
Mycoses; 2001; 44(1-2):37-45. PubMed ID: 11398639
[TBL] [Abstract][Full Text] [Related]
29. Synergistic antifungal activity of berberine derivative B-7b and fluconazole.
Li LP; Liu W; Liu H; Zhu F; Zhang DZ; Shen H; Xu Z; Qi YP; Zhang SQ; Chen SM; He LJ; Cao XJ; Huang X; Zhang JD; Yan L; An MM; Jiang YY
PLoS One; 2015; 10(5):e0126393. PubMed ID: 25992630
[TBL] [Abstract][Full Text] [Related]
30. Up-regulation of ERG11 gene among fluconazole-resistant Candida albicans generated in vitro: is there any clinical implication?
Ribeiro MA; Paula CR
Diagn Microbiol Infect Dis; 2007 Jan; 57(1):71-5. PubMed ID: 16839736
[TBL] [Abstract][Full Text] [Related]
31. In vitro fluconazole susceptibility of 1565 clinical isolates of Candida species evaluated by the disk diffusion method performed using NCCLS M44-A guidelines.
Testore GP; Dori L; Buonomini AR; Schito GC; Soro O; Fortina G; Andreoni S; Carlone N; Tullio V; Andreoni M
Diagn Microbiol Infect Dis; 2004 Nov; 50(3):187-92. PubMed ID: 15541604
[TBL] [Abstract][Full Text] [Related]
32. In vitro activity of voriconazole against Candida species isolated in Taiwan.
Yang YL; Cheng HH; Lo HJ
Int J Antimicrob Agents; 2004 Sep; 24(3):294-6. PubMed ID: 15325436
[TBL] [Abstract][Full Text] [Related]
33. Carboxylic acid and phosphate ester derivatives of fluconazole: synthesis and antifungal activities.
Nam NH; Sardari S; Selecky M; Parang K
Bioorg Med Chem; 2004 Dec; 12(23):6255-69. PubMed ID: 15519168
[TBL] [Abstract][Full Text] [Related]
34. Activity of amphotericin B, anidulafungin, caspofungin, micafungin, posaconazole, and voriconazole against Candida albicans with decreased susceptibility to fluconazole from APECED patients on long-term azole treatment of chronic mucocutaneous candidiasis.
Rautemaa R; Richardson M; Pfaller MA; Perheentupa J; Saxén H
Diagn Microbiol Infect Dis; 2008 Oct; 62(2):182-5. PubMed ID: 18597968
[TBL] [Abstract][Full Text] [Related]
35. Disk diffusion method for fluconazole susceptibility testing of Candida albicans strains.
Yücesoy M; Guldaş NS; Yuluğ N
J Chemother; 2001 Apr; 13(2):161-6. PubMed ID: 11330363
[TBL] [Abstract][Full Text] [Related]
36. Synthesis, antifungal activity of caffeic acid derivative esters, and their synergism with fluconazole and nystatin against Candida spp.
Sardi JC; Gullo FP; Freires IA; Pitangui NS; Segalla MP; Fusco-Almeida AM; Rosalen PL; Regasini LO; Mendes-Giannini MJ
Diagn Microbiol Infect Dis; 2016 Dec; 86(4):387-391. PubMed ID: 27638348
[TBL] [Abstract][Full Text] [Related]
37. Fluconazole-containing agar Sabouraud dextrose plates are not useful when screening for susceptibility in Candida albicans.
Bordallo-Cardona MA; Marcos-Zambrano LJ; Gómez G de la Pedrosa E; Escribano P; Bouza E; Guinea J; Cantón R
Rev Esp Quimioter; 2017 Apr; 30(2):127-130. PubMed ID: 28181429
[TBL] [Abstract][Full Text] [Related]
38. In vitro synergism of fluconazole and baicalein against clinical isolates of Candida albicans resistant to fluconazole.
Huang S; Cao YY; Dai BD; Sun XR; Zhu ZY; Cao YB; Wang Y; Gao PH; Jiang YY
Biol Pharm Bull; 2008 Dec; 31(12):2234-6. PubMed ID: 19043205
[TBL] [Abstract][Full Text] [Related]
39. In vitro activity of verapamil alone and in combination with fluconazole or tunicamycin against Candida albicans biofilms.
Yu Q; Ding X; Xu N; Cheng X; Qian K; Zhang B; Xing L; Li M
Int J Antimicrob Agents; 2013 Feb; 41(2):179-82. PubMed ID: 23265915
[TBL] [Abstract][Full Text] [Related]
40. Berberine-fluconazole microparticle-based combination therapy to treat candidiasis infections.
Simões Gobbi LP; Costa EHE; Fernandez CMM; Lorenzetti FB; Fonseca DP; Gomes AV; Baldoqui DC; Fernandes CS; Ueda-Nakamura T; Nakamura CV; Lima MMS; Filho BPD
J Appl Microbiol; 2023 Dec; 134(12):. PubMed ID: 38040656
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
